Performance of Salivary Extracellular RNA Biomarker Panels for Gastric Cancer Differs between Distinct Populations.
biomarkers
exRNA
gastric cancer
saliva
validation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jul 2022
26 Jul 2022
Historique:
received:
20
05
2022
revised:
27
06
2022
accepted:
19
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Gastric cancer (GC) has the fifth highest incidence among cancers and is the fourth leading cause of cancer-related death GC has predominantly a higher number of cases in certain ethnic groups such as the Korean population. GC found at an early stage is more treatable and has a higher survival rate as compared with GC found at a late stage. However, a diagnosis of GC is often delayed due to the lack of early symptoms and available screening programs in United States. Extracellular RNA (exRNA) is an emerging paradigm; exRNAs have the potential to serve as biomarkers in panels aimed at early detection of cancer. We previously reported the successful use of a panel of salivary exRNA for detecting GC in a high-prevalence Korean cohort, and that genetic changes reflected cancer-associated salivary exRNA changes. The current study is a case-control study of salivary exRNA biomarkers for detecting GC in an ethnically distinct U.S. cohort. A model constructed for the U.S. cohort combined demographic characteristics and salivary miRNA and mRNA biomarkers for GC and yielded an area under the receiver operating characteristic (ROC) curve (AUC) of 0.78. However, the constituents of this model differed from that constructed for the Korean cohort, thus, emphasizing the importance of population-specific biomarker development and validation.
Identifiants
pubmed: 35892889
pii: cancers14153632
doi: 10.3390/cancers14153632
pmc: PMC9331389
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : U01 CA086400
Pays : United States
Références
World J Gastroenterol. 2014 Oct 14;20(38):13842-62
pubmed: 25320521
Br J Cancer. 2014 Apr 29;110(9):2291-9
pubmed: 24595006
J Am Dent Assoc. 1998 Aug;129(8):1138-43
pubmed: 9715016
Chin J Cancer Res. 2020 Dec 31;32(6):695-704
pubmed: 33446993
Mol Ther Nucleic Acids. 2013 Jul 23;2:e109
pubmed: 23881452
Tumour Biol. 2017 Jul;39(7):1010428317714626
pubmed: 28671042
Am J Clin Oncol. 1997 Aug;20(4):348-53
pubmed: 9256887
Eur J Cancer. 2003 Jan;39(2):184-91
pubmed: 12509950
J Extracell Vesicles. 2015 Aug 28;4:27494
pubmed: 26320939
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
J Cancer Metastasis Treat. 2020;6:
pubmed: 33490601
RNA. 2008 Jul;14(7):1424-32
pubmed: 18456845
BMC Cancer. 2012 Jan 17;12:22
pubmed: 22251860
Methods Mol Biol. 2010;666:21-30
pubmed: 20717775
Am J Dent. 2009 Aug;22(4):241-8
pubmed: 19824562
Gut. 2021 May;70(5):829-837
pubmed: 33028667
Clin Chem. 2018 Oct;64(10):1513-1521
pubmed: 30097497
J Biol Chem. 2013 Sep 13;288(37):26888-97
pubmed: 23880764
Pathol Res Pract. 2019 Jun;215(6):152419
pubmed: 31043351
Front Oncol. 2021 Jun 18;11:684531
pubmed: 34222007
PLoS One. 2012;7(10):e46737
pubmed: 23091600
Cancer. 2013 Mar 15;119(6):1159-67
pubmed: 23224754
J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8
pubmed: 18840817
PeerJ. 2019 Jun 18;7:e7025
pubmed: 31249732
PLoS One. 2020 Aug 3;15(8):e0236811
pubmed: 32745141
Int J Mol Sci. 2020 Jun 04;21(11):
pubmed: 32512697
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
Nat Commun. 2011 Feb 01;2:180
pubmed: 21285958
Tumour Biol. 2015 Dec;36(12):9909-18
pubmed: 26168960
Clin Lung Cancer. 2009 Jan;10(1):42-6
pubmed: 19289371
J Clin Periodontol. 2018 Jul;45(7):806-817
pubmed: 29779262
Front Genet. 2019 Jan 22;10:5
pubmed: 30723491